

Company Overview

Medexus Pharmaceuticals Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading prescription products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Medexus Achieves Record Revenue of \$31.5 Million for the Third Quarter Fiscal 2021

Mar 1 2021, 5:00 PM EST

Medexus Announces Expanded Availability of Gleolan® in Canada

Feb 25 2021, 9:00 AM EST

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Feb 24 2021, 9:00 AM EST

Investor Relations

Crescendo Communications, LLC
David Waldman / Natalya Rudman
T: 212-671-1020
mdp@crescendo-ir.com

Management Team

Ken d'Entremont

Chief Executive Officer and Director

Roland Boivin

Chief Financial Officer

Michael Adelman

General Manager, U.S. Operations

Michael Pine

Senior Vice President of Business Development and Strategy

Richard Labelle

Vice President Allergy, Pediatric and OTC Portfolios, Canadian Operations

Medexus Pharmaceuticals, Inc.

1 Place du Commerce
Suite 225
Verdun, QC H3E 1A2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.